These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 29142066

  • 1. Characterization of SGN-CD123A, A Potent CD123-Directed Antibody-Drug Conjugate for Acute Myeloid Leukemia.
    Li F, Sutherland MK, Yu C, Walter RB, Westendorf L, Valliere-Douglass J, Pan L, Cronkite A, Sussman D, Klussman K, Ulrich M, Anderson ME, Stone IJ, Zeng W, Jonas M, Lewis TS, Goswami M, Wang SA, Senter PD, Law CL, Feldman EJ, Benjamin DR.
    Mol Cancer Ther; 2018 Feb; 17(2):554-564. PubMed ID: 29142066
    [Abstract] [Full Text] [Related]

  • 2. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.
    Kung Sutherland MS, Walter RB, Jeffrey SC, Burke PJ, Yu C, Kostner H, Stone I, Ryan MC, Sussman D, Lyon RP, Zeng W, Harrington KH, Klussman K, Westendorf L, Meyer D, Bernstein ID, Senter PD, Benjamin DR, Drachman JG, McEarchern JA.
    Blood; 2013 Aug 22; 122(8):1455-63. PubMed ID: 23770776
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells.
    Fan D, Li Z, Zhang X, Yang Y, Yuan X, Zhang X, Yang M, Zhang Y, Xiong D.
    J Hematol Oncol; 2015 Feb 28; 8():18. PubMed ID: 25879549
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC.
    Busfield SJ, Biondo M, Wong M, Ramshaw HS, Lee EM, Ghosh S, Braley H, Panousis C, Roberts AW, He SZ, Thomas D, Fabri L, Vairo G, Lock RB, Lopez AF, Nash AD.
    Leukemia; 2014 Nov 28; 28(11):2213-21. PubMed ID: 24705479
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Development of a novel fully-human anti-CD123 antibody to target acute myeloid leukemia.
    Hutmacher C, Volta L, Rinaldi F, Murer P, Myburgh R, Manz MG, Neri D.
    Leuk Res; 2019 Sep 28; 84():106178. PubMed ID: 31326578
    [Abstract] [Full Text] [Related]

  • 10. Cytotoxicity Assessment and Apoptosis-related Gene Profiling of Antibody Treated Acute Myeloid Leukemia (AML) and Acute Lymphocytic Leukemia (ALL) Cancerous Cell Lines.
    Habibi-Anbouhi M, Kafi Z, Ghazizadeh L, Kharazi S, Behdani M, Faraji F, Shokrgozar MA.
    Iran J Allergy Asthma Immunol; 2019 Oct 30; 18(6):679-687. PubMed ID: 32245312
    [Abstract] [Full Text] [Related]

  • 11. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.
    Mardiros A, Dos Santos C, McDonald T, Brown CE, Wang X, Budde LE, Hoffman L, Aguilar B, Chang WC, Bretzlaff W, Chang B, Jonnalagadda M, Starr R, Ostberg JR, Jensen MC, Bhatia R, Forman SJ.
    Blood; 2013 Oct 31; 122(18):3138-48. PubMed ID: 24030378
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. CD16+NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted mice.
    Williams BA, Wang XH, Leyton JV, Maghera S, Deif B, Reilly RM, Minden MD, Keating A.
    Haematologica; 2018 Oct 31; 103(10):1720-1729. PubMed ID: 29976748
    [Abstract] [Full Text] [Related]

  • 14. Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform.
    Al-Hussaini M, Rettig MP, Ritchey JK, Karpova D, Uy GL, Eissenberg LG, Gao F, Eades WC, Bonvini E, Chichili GR, Moore PA, Johnson S, Collins L, DiPersio JF.
    Blood; 2016 Jan 07; 127(1):122-31. PubMed ID: 26531164
    [Abstract] [Full Text] [Related]

  • 15. Auger electron radioimmunotherapeutic agent specific for the CD123+/CD131- phenotype of the leukemia stem cell population.
    Leyton JV, Hu M, Gao C, Turner PV, Dick JE, Minden M, Reilly RM.
    J Nucl Med; 2011 Sep 07; 52(9):1465-73. PubMed ID: 21816968
    [Abstract] [Full Text] [Related]

  • 16. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.
    Tasian SK, Kenderian SS, Shen F, Ruella M, Shestova O, Kozlowski M, Li Y, Schrank-Hacker A, Morrissette JJD, Carroll M, June CH, Grupp SA, Gill S.
    Blood; 2017 Apr 27; 129(17):2395-2407. PubMed ID: 28246194
    [Abstract] [Full Text] [Related]

  • 17. AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML.
    Pereira DS, Guevara CI, Jin L, Mbong N, Verlinsky A, Hsu SJ, Aviña H, Karki S, Abad JD, Yang P, Moon SJ, Malik F, Choi MY, An Z, Morrison K, Challita-Eid PM, Doñate F, Joseph IB, Kipps TJ, Dick JE, Stover DR.
    Mol Cancer Ther; 2015 Jul 27; 14(7):1650-60. PubMed ID: 25934707
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL.
    Mehta NK, Pfluegler M, Meetze K, Li B, Sindel I, Vogt F, Marklin M, Heitmann JS, Kauer J, Osburg L, Zekri L, Bühring HJ, Mueller S, Hörner S, Baeuerle PA, Michaelson JS, Jung G, Salih HR.
    J Immunother Cancer; 2022 Mar 27; 10(3):. PubMed ID: 35288466
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.